Clinical trials: Chidamide
Complete Remission Rate， CRR, Progression Free Survival
Sintilimab, Chidamide, and Azacitidine for Untreated Stage I-II Extranodal NK/T-Cell Lymphoma
This is an open-label, single-arm, multi-center Phase II clinical trial evaluating the efficacy and safety of a novel sequential regimen as first-line therapy for treatment-naïve patients with Extranodal NK/T-cell Lymphoma…
- Conditions
- Complete Remission Rate， CRR, Progression Free Survival, Overall Survival, Adverse Event
- Trial name
- SCENT-3 (NCT07542912)
- Testing
- SCA Induction followed by Response-Adapted Therapy
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Sun Yat-sen University
Newly Diagnosed MYC/BCL2 Double-expressor DLBCL
Serplulimab, Chidamide, and Rituximab Followed by Sequential R-CHOP for Newly Diagnosed Elderly MYC/BCL2 Double-Expressor DLBCL
This study is a phase II clinical trial and is divided into three stages. Stage 1: Chemotherapy-free phase. All subjects will receive "Serplulimab, Chidamide, and Rituximab (SCR) therapy".
- Trial name
- SCREEN (NCT07538180)
- Testing
- SCR Regimen Sequential with R-CHOP and Maintenance Therapy
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Sun Yat-sen University
Acute Lymphoblastic Leukemia
A Prospective Clinical Study of Bridging alloHSCT After Treatment With Obinutuzumab in Combination With Chidamide and Venetoclax in RR Ph-ALL and B-cell Lymphoma Patients
This study is a multicenter, prospective, interventional clinical trial aimed at recruiting relapsed/refractory Ph-ALL patients at multiple stem cell transplantation centers, including the Stem Cell Transplantation Center of the…
- Trial name
- NCT06087419
- Testing
- chidamide, Venetoclax Oral Tablet, Inotuzumab Ozogamicin
- Volunteers
- 42 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Peripheral T-Cell Lymphoma Refractory
An Open-label, Single-arm, Multicenter Phase II Clinical Study of Azacitidine, Chidamide Combined With PD-1 Monoclonal Antibody in the Treatment of Refractory/Relapsed Peripheral T-cell Lymphoma.
An Open-Label, Single-Arm, Multicenter Phase II Clinical Study to Evaluate the Efficacy of Azacitidine, Chidamide, and PD-1 Monoclonal Antibody in the Treatment of Refractory/Relapsed Peripheral T-Cell Lymphoma.
- Trial name
- NCT07598578
- Testing
- Azacitidine (AZA)
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Second Affiliated Hospital of Soochow University
Experimental Tumor
Chidamide for Patients With Recurrent and Metastatic Epstein-Barr Virus (EBV)-Associated Solid Tumors
Study of Chidamide as a Single-agent Treatment for Patients With Recurrent and Metastatic Epstein-Barr virus (EBV)-associated Solid Tumors
- Trial name
- NCT03494634
- Testing
- Chidamide
- Where
- China
- Volunteers
- 66 people
- Sponsor
- Sun Yat-sen University
Breast Cancer
Tucidinostat and Fulvestrant in Hormone-receptor Positive Advanced Breast Cancer
The purpose of the study is evaluate the efficacy and safety of tucidinostat in combination with fulvestrant in patients with hormone-receptor positive advanced breast cancer.
- Trial name
- NCT04999540
- Testing
- Tucidinostat, Fulvestrant
- Volunteers
- 73 people
- Sponsor
- Guangdong Women and Children Hospital
AML (Acute Myeloid Leukemia)
Chidamide, Venetoclax, Azacitidine, and Homoharringtonine for High-risk Fit AML
This study aims to explore a superior first-line induction remission regimen by incorporating Chidamide into the modified VAH chemotherapy combined with targeted therapy regimen, leveraging its dual epigenetic modulation…
- Trial name
- NCT07643636
- Testing
- Chidamide (Chi)+VAH
- Volunteers
- 46 people
- Sponsor
- Dongguan People's Hospital
Acute Myeloid Leukemia (Relapsed/Refractory)
Study of Selinexor Combined With Chidamide in Relapsed/Refractory Acute Leukemia (AML) Patients
This is a prospective, single-arm, multi-center clinical trial to evaluate the efficacy and safety of selinexor combined with chidamide in the treatment of unfit R/R AML.
- Trial name
- NCT05951855
- Testing
- Selinexor, Chidamide
- Where
- China
- Volunteers
- 42 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Non Small Cell Lung Cancer
Trial of Chidamide in Combination With Envafolimab in Patients With PD-1 Inhibitor Resistant Advanced NSCLC.
This study is to evaluate the preliminary efficacy and safety of Chidamide combined with Envafolimab in patients with PD-1 inhibitor resistant advanced NSCLC.
- Trial name
- NCT05068427
- Testing
- Chidamide, Envafolimab
- Where
- 12 sites in China
- Volunteers
- 34 people
- Sponsor
- Chipscreen Biosciences, Ltd.
Bladder Cancer Stage IV
Chidamide With Immunotherapy for Patients With Locally Advanced or Metastatic Urothelial Carcinoma
Study of Chidamide Combined With Immunotherapy in Patients With Locally Advanced or Metastatic Urothelial Carcinoma Who Had Previously Received Platinum-based Chemotherapy
- Trial name
- NCT04562311
- Testing
- Chidamide
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Sun Yat-sen University
Colorectal Cancer
A Study of Tucidinostat in Combination With Sintilimab and Bevacizumab in MSS/pMMR Colorectal Cancer Patients
A randomised, open-label, multicenter phase III study to evaluate the efficacy and safety of tucidinostat in combination with sintilimab and bevacizumab versus fruquintinib monotherapy in MSS/pMMR colorectal cancer patients.
- Trial name
- NCT06497985
- Testing
- Tucidinostat, Sintilimab, Bevacizumab
- Where
- China
- Volunteers
- 430 people
- Sponsor
- Chipscreen Biosciences, Ltd.
Diffuse Large B-cell Lymphoma
Chidamide in Patients With Recurrent and Refractory Diffuse Large b
A Multicenter, Prospective, Observational Clinical Protocol for Chidamide in Combination With Rituximab and Lenalidomide (cR2) in Real-world Practice in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
- Trial name
- NCT05690191
- Testing
- Chidamide, Lenalidomide, Rituximab
- Where
- China
- Volunteers
- 169 people
- Sponsor
- Second Affiliated Hospital of Soochow University
Newly Diagnosed Peripheral T-cell Lymphoma
A Randomized Clinical Trial Comparing Chi-BEAM With BEAM Regimen Combined With ASCT for the Treatment of ND PTCL
The goal of this clinical trial is to compare Chi-BEAM With BEAM Regimen Combined With ASCT for the Treatment of ND PTCL. The main question it aims to answer are: •Whether Chi-BEAM improves patient survival compared to BEAM group…
- Trial name
- NCT05931263
- Testing
- C-BEAM Regimen, BEAM Regimen
- Where
- China
- Volunteers
- 104 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Thrombocytopenia
A Multicenter Randomized Open-label Study of Chidamide Plus HD-DEX Versus HD-DEX in ITP
Recently, histone deacetylase inhibitors (HDACi) has been used for their anti-inflammatory and immunomodulatory activities. It has been shown that HDACi can alleviate graft-versus-host disease by enhancing the number and function…
- Trial name
- NCT05411874
- Testing
- Chidamide, HD-DXM
- Volunteers
- 100 people
- Sponsor
- Shandong University
Neuroblastoma in Children
Tucidinostat Plus Etoposide in the Treatment of Neuroblastoma in Childhood.
Neuroblastoma is a malignant tumor that develops in infants and kids. Dysregulation of histone acetylation is associated with a series of malignant tumors.
- Trial name
- CSIIT-Q36 (NCT05338541)
- Testing
- Tucidinostat and etoposide
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Yizhuo Zhang
Breast Cancer
Trial of Chidamide in Combination With Exemestane in Patients With Advanced Breast Cancer
This study was to evaluate the efficacy and safety of Chidamide in combination with exemestane in postmenopausal patients with hormone-receptor positive advanced breast cancer.
- Trial name
- NCT02482753
- Testing
- Chidamide, exemestane
- Where
- 22 sites in China
- Volunteers
- 365 people
- Sponsor
- Chipscreen Biosciences, Ltd.
AML, Adult, Minimal Residual Disease
A Study of Chidamide With AZA in MRD Positive AML After Transplant
acute myeloid leukemia (AML) is a malignant tumor of the hematopoietic system with high heterogeneity in cytogenetics and molecular biology.Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is still the primary…
- Trial name
- NCT06066905
- Testing
- chidamide and azacitidine
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Guangdong Provincial People's Hospital
Leukemia, Myeloid, Acute, Relapsed Adult AML
Venetoclax Combining Chidamide and Azacitidine (VCA) in the Treatment of R/R AML
The purpose of this study is to evaluate the safety and efficacy of Venetoclax Combining Chidamide and Azacitidine (VCA) in the Treatment of relapsed and/or refractory AML
- Conditions
- Leukemia, Myeloid, Acute, Relapsed Adult AML, Refractory Leukemia
- Trial name
- NCT05305859
- Testing
- venetoclax combining chidamide and azacitidine (VCA)
- Where
- China
- Volunteers
- 30 people
- Sponsor
- The First Affiliated Hospital of Xiamen University
B-cell Non-Hodgkin's Lymphoma
Chidamide Plus DICE Regimen for Patients With Relapse or Refractory B-cell Non-Hodgkin's Lymphoma (NHL)
This is a prospective phase II clinical trial to observe the efficacy and safety of Chidamide combined with DICE (Dexamethasone, Ifosfamide, Cisplatin and Etoposide) in patients with relapsed or refractory B-cell Non-Hodgkin's…
- Trial name
- NCT03105596
- Testing
- Chidamide plus DICE Regimen
- Volunteers
- 46 people
- Sponsor
- Peking University
Breast Cancer, Chemotherapy Effect
Chidamide in Combination With Vincristine Metronomic Chemotherapy for Advanced Triple-negative Breast Cancer
The mechanism of action of cidabenamide and the advantages of vincristine metronomic chemotherapy make it possible to combine the two drugs.
- Trial name
- NCT05747313
- Testing
- Chidamide
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences